

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM832958

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Cumberland Pharmaceuticals Inc.		08/14/2023	Corporation: TENNESSEE
RECEIVING PARTY DATA			
Name:	Nordic Group B.V.		
Street Address:	Siriusdreef 41		
City:	Hoofddorp		
State/Country:	NETHERLANDS		
Postal Code:	2132 WT		
Entity Type:	besloten vennootschap (bv): NETHERLANDS		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	6034222	REDITREX	
CORRESPONDENCE DATA			
Fax Number:	2026375910		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	202-637-5600		
Email:	HLDCTMGroup@hoganlovells.com		
Correspondent Name:	Anna Kurian Shaw of Hogan Lovells US LLP		
Address Line 1:	555 13th Street NW		
Address Line 4:	Washington, D.C. 20004		
ATTORNEY DOCKET NUMBER:	767132.000009		
NAME OF SUBMITTER:	Hadley Dreibelbis		
SIGNATURE:	/Hadley Dreibelbis/		
DATE SIGNED:	08/18/2023		
Total Attachments: 4			
source=REDACTED signed Nordic Group BV - CPI Trademark Assignment Agrmt PE 8-14-2023#page1.tif			
source=REDACTED signed Nordic Group BV - CPI Trademark Assignment Agrmt PE 8-14-2023#page2.tif			
source=REDACTED signed Nordic Group BV - CPI Trademark Assignment Agrmt PE 8-14-2023#page3.tif			
source=REDACTED signed Nordic Group BV - CPI Trademark Assignment Agrmt PE 8-14-2023#page4.tif			

CH \$40.00 6034222

Trademark Assignment Agreement

WHEREAS, Cumberland Pharmaceuticals Inc., a Tennessee corporation with a principal place of business at 1600 West End Avenue, Suite 1300, Nashville, Tennessee, 37203-7003, United States of America (the “Assignor”), owns the trademark that is listed on the attached Exhibit A, including any and all common law rights, applications, and registrations therefore (the “Mark”); *and*

WHEREAS, Nordic Group B.V., a Dutch besloten vennootschap (bv) with a principal place of business at Siriusdreef 41, 2132 WT Hoofddorp, Netherlands (the “Assignee”), desires to acquire all right, title, and interest in and to the Mark; *and*

WHEREAS, Assignor and Assignee have entered into a License Agreement dated November 15, 2016, as amended (“License Agreement”) which was terminated by the parties as of June 30, 2022. Pursuant to the License Agreement, Assignee accepts the ownership of the Mark and assumes and agrees to perform all obligations related to or associated with said Mark.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor does hereby irrevocably sell, assign, transfer, set over and relinquishes exclusively unto the Assignee, its successors, legal representatives and assigns, Assignor’s entire right, title and interest in and to the Mark including the goodwill of the business symbolized by the Mark; the absolute entitlement to any registered trademark or designs granted pursuant to any of the applications comprised in the Mark; all statutory and common law rights attaching to the Mark, the right to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action (including passing off or unfair competition) arising from ownership, of any of the Mark whether occurring before, on or after the date of this assignment; the same to be held and enjoyed by the Assignee, for its own use and behalf and for the use and behalf of its successors, legal representatives and assigns, for the full term of the Mark, including any renewals, reversions, extensions or revivals, as fully and entirely as if the same would have been held and enjoyed by the Assignor had this sale and assignment not been made. For the sake of clarity, this transfer encompasses the right to sue third parties for and recover and retain all damages and other remedies for future infringement and violations in law or equity concerning the Mark.




AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives and assigns that if counsel for the Assignee, or the counsel for its successors, legal representatives and assigns, shall advise that any proceeding, filing or other legal action in connection with the Mark is lawful and desirable for the maintenance, enforcement and defense of the same, Assignor will, to the extent reasonable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the maintenance, enforcement and defense of the Mark and any trademark or design registrations resulting therefrom, without charge to the Assignor, its successors, legal representatives and assigns, but at the cost and expense of the Assignee, its successors, legal representatives and assigns.


On or before November 1st, 2023, Assignee shall record this Agreement (including the preparation, execution and filing of all documents and performance of all acts necessary in this connection) with the United States Trademark Office. At the same time Assignee will file a change of the address of correspondence for the Mark with the United States Trademark Office. All related costs shall be borne by Assignee. Assignor shall on Assignee’s request and at Assignee’s expense, do and execute or arrange for

the doing and execution of all acts, deeds and documents reasonably necessary for the recordation of this Agreement if such request is made within thirty (30) days after the date hereof.

Assignee accepts the ownership of the Mark and assumes and agrees to perform all obligations related to or associated with said Mark.


Governing Law. The interpretation and construction of this Agreement will be governed by the laws of the United Kingdom, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction.





IN WITNESS WHEREOF, the parties hereby have executed this Assignment as of August 14th, 2023.

Cumberland Pharmaceuticals Inc.

By:  DocuSigned by:
A.J. Kazimi
DN: cn=A.J. Kazimi,
o=Cumberland
Pharmaceuticals Inc.,
ou=CA,
ou=US, email=ajkazimi@cumberlandpharma.com,
c=US,
148725 00:00

Name: A.J. Kazimi


Title: Chief Executive Officer August 14, 2023

Nordic Group B.V.

By:

Name: dave.faulkner@nordicpharma.com

Title: Head Of Commercial Operations International

DocuSigned by:

2604C218E89A427
2023 August 16 | 13:01:54 CEST

Charlotte Phelps

CEO


DocuSigned by:

1B58D4B691AE4C7
2023 August 16 | 11:39:01 CEST

Exhibit A- Mark

Jurisdiction	Mark	Registration No.	Registration Date
US	REDITREX	6034222	14 April 2020

[End of EXHIBIT A]